SciELO - Scientific Electronic Library Online

vol.142 número5Estudio longitudinal de tres familias con parkinsonismo familiarFisiopatología de las enfermedades por priones índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados



Links relacionados

  • Não possue artigos similaresSimilares em SciELO


Gaceta médica de México

versão impressa ISSN 0016-3813


CABALLERO-CABALLERO, Rocío; HERNANDEZ-RIVERA, E.Gabriela  e  LOPEZ-KARPOVITCH, Joseph X.. Ten year experience with ocular lymphomas and ocular adnexae lymphomas. Gac. Méd. Méx [online]. 2006, vol.142, n.5, pp. 393-397. ISSN 0016-3813.

Background. Ocular lymphomas and ocular adnexae lymphomas (OL and O AL) constitute 7-8% of all extranodal lymphomas. Objective. Describe the clinical, morphologic and immunophenotypic characteristics of OAL seen in our hospital. Material and methods. Retrospective analysis of patient records with OL and OAL between July 1994 and July 2005. The following data was analyzed: Clinical presentation, therapy, treatment response, overall survival and disease free survival. Results. Ten patientswith OL and OAL were identified. Of these, 8 were women and 2 men. Median age was 50. Eight of 10 patients achieved complete remission, 6 of the 6 presenting MALT Lymphoma. Two patients with stage IV had refractory disease. Conclusions. In our series 0.02% of lymphomas were OL and OAL of a total 498 LNH. MALT lymphomas appear at a more advanced age, sixty percent of the cases were MALT lymphomas and were diagnosed during their early stages. Patients were followed during 21 months, global survival was 100%, free illness survival had a mean of 868 days and a survival median of 442 days.

Palavras-chave : Extranodal lymphoma; ocular lymphoma; adnexae; lymphoid tissue; conjuntival hyperemia.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License